Novo Nordisk Eyes Residual CV Risk In Atherosclerosis With Ziltivekimab

Semaglutide Nears Market For Obesity

 
• By John Davis
  
Nyhavn in Copenhagen
Copenhagen, where Novo Nordisk is headquartered • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Cardiovascular

More from Therapy Areas